%0 Journal Article
%T A Translation Readiness Dossier for Tracking Pharmaceutical Concepts through Reproducibility, Manufacturing Feasibility, Biological Validation, and Clinical Relevance
%A Ethan Wright
%A Chloe Bennett
%A Jack Turner
%A Olivia Harris
%J International Journal of Pharmaceutical Research and Allied Sciences
%@ 2277-3657
%D 2025
%V 14
%N 4
%R 10.51847/Z5IOypbB4U
%P 1-13
%X Pharmaceutical concepts commonly advance through discovery and development by completing predefined activities, entering formal phases, or satisfying locally defined technical milestones. These events are operationally useful but do not necessarily demonstrate that the supporting evidence is reproducible, biologically relevant, manufacturable, clinically interpretable, or adequate for the next consequential decision. This Original Translation-Readiness Architecture Article proposes a Translation-Readiness Dossier for organizing evidence around a defined pharmaceutical concept and intended therapeutic use. The architecture separates foundational robustness, biological validation, manufacturing feasibility, safety and pharmacology, clinical relevance, uncertainty, and implementation requirements rather than compressing them into a single maturity label. Each domain is linked to evidence provenance, context of use, unresolved assumptions, and explicit decision boundaries. Safety, pharmacology, and clinical relevance are treated as related but non-equivalent evidence dimensions, preventing mechanistic plausibility, favorable model output, or technical performance from being interpreted automatically as patient-relevant readiness. Evidence gaps are retained visibly, while proposed readiness grades describe domain-specific evidentiary states without functioning as validated scores or predictions of success. Reversible decision gates allow progression, conditional progression, additional evidence generation, redesign, hold, or termination, and a version-controlled updating process records how new findings alter previous assumptions. The original contribution is an integrated, non-compensatory architecture intended to improve traceability and expose cross-domain discordance. Its value requires prospective evaluation of reliability, feasibility, resistance to selective reporting, inter-rater consistency, and consequences for real development decisions. The dossier is not a regulatory submission, clinical recommendation, validated predictive instrument, or universally applicable deployment standard. 
%U https://ijpras.com/article/a-translation-readiness-dossier-for-tracking-pharmaceutical-concepts-through-reproducibility-manufa-8zdknlraxlklwe9